Warranty Model: A potential precision financing solution for durable cell and gene therapies
Durable cell and gene therapies are poised for rapid growth—posing transformative benefits for patients and exacerbating financial challenges for payers, providers, patients, and developers by disrupting the classic ‘pay-as-you-go’ drug payment paradigms. FoCUS investigated a new warranty solution that not only addresses performance risk challenges, but also reduces data aggregation complexity and contains Medicaid Best Price exposure, thus providing risk sharing flexibility between payers and developers.
FoCUS Virtual Design Lab explores Precision Financing Solutions for large populations and RWE implementation
On October 15th and 16th, FoCUS hosted a Virtual Design Lab, an online implementation of NEWDIGS’s unique case study solution design methodology. 80 participants from across the healthcare sector collaborated to extend Precision Financing Solutions to large populations using a disease area case study and a Medicare Fee for Service case study. Both days featured presentations and discussions about the role of Real World Evidence (RWE) in making new cell and gene therapies accessible and sustainable. The Design Lab also featured an update to NEWDIGS research on the new therapy pipeline.
IN THE COMMUNITY
Jane Barlow spoke at the Oxford Global Cell Series virtual conference on October 7 in the panel “Realizing the Full Promise of RWE in Drug Development”; on October 20 she participated in “Successful gene therapy manufacturing and commercialization – a round table discussion” at the Cell & Gene Therapy Bioprocessing & Commercialization virtual conference; on October 27 she participated in “Precision financing solutions for gene & cell therapies” hosted by the National Association of Managed Care Physicians Value Based Care Council; on October 28 she spoke at the 4th Annual Gene Therapy for Rare Disorders Europe conference in the session “Bridging the gap between market access and patient access”.
John Glasspool and Terry Cothran participated in a panel discussion hosted by the National Organization for Rare Disorders, “Covering High-Cost Therapies: Implications for Rare Disease Patients and Payers,” on October 29
On December 3 Jane Barlow will moderate the panel “Reimbursement Models for Cell and Gene Therapies” at the 16th Annual Trade and Channel Strategies 2020 Innovative Pharmacy and Distribution Models Driven by Market Dynamics, Product Type, Site of Care and Reimbursement Virtual Event
Mark Trusheim and Jane Barlow will participate in the FDA / CMS Summit on December 7–9. Mark will participate in a panel entitled “Addressing Reimbursement Barriers for Cell and Gene Therapies”, and will moderate the panel “Examine Value-Based Payment Models in the Wake of the Pandemic”. Jane will participate in the panel “Realizing the Full Promise of RWE in Drug Development” PDF Overview